Retinal Cell Articles & Analysis
14 news found
Summary Attending a loupe fair is an exciting and essential milestone for dental and hygiene students. Loupes are a critical tool in modern dentistry, enhancing precision and ergonomics during procedures. Choosing the right pair of loupe and LED headlight can significantly impact your comfort and performance. Here’s a guide to help dental and hygiene students prepare for a loupe fair, ...
VG801 is based on the Company’s novel adeno-associated virus (AAV) technology platforms, enabling the efficient expression of large genes in retinal photoreceptors after intravitreal injection. The data from a Stargardt disease model will be presented in a poster session at the European Society of Gene & Cell Therapy (ESGCT) Congress, Edinburgh, October ...
Patients with RP have damaged photoreceptors, the primary cells required for vision, which are lost and cannot regenerate. However, inner retinal neurons downstream to photoreceptors, especially retinal ganglion cells (RGCs), persist in significant numbers through late-stage disease. ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has expanded its existing collaboration with Advanced BioMatrix, a division of BICO Group AB (STO: BICO), for Lineage’s HyStem cell/drug delivery ...
The presentation, “Safety and Efficacy of a Phase 1/2a Clinical Trial of Transplanted Allogeneic Retinal Pigmented Epithelium (RPE, OpRegen) Cells in Advanced Dry Age-Related Macular Degeneration (AMD)” was featured as part of the Retinal Prostheses and Transplantation Session, by Allen C. ...
The presentation titled, “Phase 1 Study of Intravitreal UBX1325: A Novel Agent Against Retinal Cell Senescence in AMD and DME,” featured safety, efficacy, and durability data from the Phase 1 single ascending dose study of UBX1325 in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD), including data results ...
Genentech Will Pay Lineage $50 Million Upfront Eligible to Receive a Total of $670 Million in Upfront and Milestone Payments Conference Call to Discuss Collaboration Planned for 8 a.m. ET Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), today announced that Lineage and its subsidiary, Cell Cure Neurosciences Ltd., have entered into an ...
– Oct. 29, 2021 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced the publication of the peer-reviewed manuscript, “Co-grafts of Human Stem Cell-Derived Retina Organoids and Retinal Pigment Epithelium for Retinal Reconstruction in Immunodeficient ...
As part of the alliance, the companies will combine their collective expertise to discover and develop off-the-shelf iPS cell therapies for ocular diseases. Under this agreement, BlueRock Therapeutics will have the option to exclusively license from both parties three (3) retinal cell therapy programs focused on dry age-related macular ...
As part of the alliance, the companies will combine their collective expertise to discover and develop off-the-shelf iPS cell therapies for ocular diseases. Under this agreement, BlueRock Therapeutics will have the option to exclusively license from both parties three (3) retinal cell therapy programs focused on dry age-related macular ...
About Dry Age-Related Macular Degeneration (AMD) and Geographic Atrophy (GA) Dry AMD is a leading cause of permanent vision loss in people over the age of 50 and is a devastating diagnosis.[1] There are currently no approved treatments for dry AMD, which is the most common form, impacting approximately 85-90% of people with AMD.[2] As dry AMD advances, it leads to GA, an irreversible ...
Professor Ann Logan, from the University of Warwick, leader of the research team and senior author of the publication, said, “Inflammation plays a vital role in healing, but when it becomes uncontrolled the immune system starts damaging healthy cells, tissues, and organs causing scarring that compromises function. Excessive inflammation has adverse consequences in the brain ...
The companies will use ViGeneron’s proprietary vgAAV, novel engineered AAV capsids, to efficiently transduce retinal cells via intravitreal injections. “Gene therapy has become a clinical reality. ...
Its lead product VG901 targets a disease gene for Retinitis pigmentosa (RP), for which there is currently no approved treatment option. VG901 is developed from ViGeneron’s proprietary next generation vgAAV vector platform that allows a superior transduction of retinal cells and intravitreal, a less invasive treatment administration. ...